King-Jen Chang

King-Jen Chang

Auto-generated profile, based on publicly available information

King-Jen Chang

Taiwan Breast Cancer Foundation, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
IHI-Ching Hou
I-Ching Hou
HLHsin-Yi Lin
Hsin-Yi Lin
SSShan-Hsiang Shen
Shan-Hsiang Shen
KCKing-Jen Chang
King-Jen Chang
HTHao-Chih Tai
Hao-Chih Tai
PDPatricia C Dykes
Patricia C Dykes
Background: There are over 2 million newly diagnosed patients with breast cancer worldwide with more than 10,000 cases in Taiwan each year. During 2017-2018, the National Yang-Ming University, the Taiwan University of Science and Technology, and the Taiwan Breast Cancer Prevention Foundation collaborated to develop a breast cancer self-management support (BCSMS) mHealth app for Taiwanese women with breast cancer.Objective: The aim of this study was to investigate the quality of life (QoL) of women with breast cancer in Taiwan after using the BCSMS app.Methods: After receiving a first diagnosis of breast cancer, women with stage 0 to III breast cancer, who were recruited from social networking sites or referred by their oncologists or oncology case managers, were randomized 1:1 into intervention and control groups. Intervention group subjects used the BCSMS app and the control group subjects received usual care. Two questionnaires—the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) and the EORTC Breast Cancer-Specific Quality-of-Life Questionnaire (QLQ-BR23)—were distributed to subjects in both arms. Paper-based questionnaires were used at baseline; paper-based or Web-based questionnaires were used at 1.5-month and 3-month follow-up evaluations. All evaluations were self-assessed and anonymous, and participants were blinded to their allocation groups. Descriptive analysis, the Pearson chi-square test, analysis of variance, and the generalized estimating equation were used to analyze the data. Missing values, with and without multi-imputation techniques, were used for sensitivity analysis.Results: A total of 112 women were enrolled and randomly allocated to either the experimental group (n=53) or control group (n=59). The follow-up completion rate was 89.3% (100/112). The demographic data showed homogeneity between the two groups in age (range 50-64 years), breast cancer stage (stage II), marital status (married), working status (employed), and treatment status (receiving treatments). The mean total QoL summary scores from the QLQ-C30 (83.45 vs 82.23, P=.03) and the QLQ-BR23 (65.53 vs 63.13, P=.04) were significantly higher among the experimental group versus the control group, respectively, at 3 months.Conclusions: This research provides support for using a mobile health care app to promote the QoL among women in Taiwan after a first diagnosis of breast cancer. The BCSMS app could be used to support disease self-management, and further evaluation of whether QoL is sustained is warranted.Trial Registration: ClinicalTrials.gov NCT004174248; https://clinicaltrials.gov/ct2/show/NCT04174248

30 April 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
IHI-Ching Hou
I-Ching Hou
MLMin-Fang Lan
Min-Fang Lan
SSShan-Hsiang Shen
Shan-Hsiang Shen
PTPei Yu Tsai
Pei Yu Tsai
KCKing Jen Chang
King Jen Chang
PDPatricia C Dykes
Patricia C Dykes
Background: Evidence has shown that breast cancer self-management support from mobile health (mHealth) apps can improve the quality of life of survivors. Although many breast cancer self-management support apps exist, few papers have documented the procedure for the development of a user-friendly app from the patient’s perspective. Objective: This study aimed to investigate the information needs of Taiwanese women with breast cancer to inform the development of a self-management support mHealth app. Methods: A 5-step design thinking approach, comprising empathy, define, ideate, prototype, and test steps, was used in the focus groups and individual interviews conducted to collect information on the requirements and expectations of Taiwanese women with breast cancer with respect to the app. A thematic analysis was used to identify information needs. Results: A total of 8 major themes including treatment, physical activity, diet, emotional support, health records, social resources, experience sharing, and expert consultation were identified. Minor themes included the desire to use the app under professional supervision and a trustworthy app manager to ensure the credibility of information. Conclusions: The strengths of the design thinking approach were user-centered design and cultural sensitivity. The results retrieved from each step contributed to the development of the app and reduction of the gap between end users and developers. An mHealth app that addresses these 8 main themes can facilitate disease self-management for Taiwanese women with breast cancer.

25 October 2002 in Cancer
Verified
Journal Article
Open access
PDF file
YCYuan‐Chiang Chung
Yuan‐Chiang Chung
KCKing‐Jen Chang
King‐Jen Chang
CYChuan‐Ching Yang
Chuan‐Ching Yang
MLMing‐Tsung Lai
Ming‐Tsung Lai
Chih-Ping HsuChih-Ping Hsu
Chih-Ping Hsu
SYShiaw‐Der Yang
Shiaw‐Der Yang
BACKGROUND Initial studies revealed that the multisubstrate proline‐directed protein kinase FA (PDPK FA) is overexpressed in various types of human carcinomas relative to normal controls. Suppression of overexpressed PDPK FA inhibits the growth of cancer cells, suggesting a role of this PDPK in human malignancy. In this study, we combine immunohistologic, molecular, cellular, animal, and clinicopathologic studies to demonstrate an essential and critical role of PDPK FA in progression and poor prognosis of human colon carcinoma. METHODS The stable antisense clones of human colon carcinoma cells with specific suppression of PDPK FA were established for tumorigenesis and invasion studies. In immunohistologic and clinicopathologic studies, the expression and localization of PDPK FA were analyzed by immunohistochemical staining of the specimens obtained from human colon carcinoma patients with Dukes Stage B/C. RESULTS Initial molecular and cellular studies revealed that the antisense clone of colon carcinoma cells (COLO‐205) with specific suppression of PDPK FA dramatically lost capabilities of adhesion, chemotaxis, and invasion when compared with the parental or control‐transfected colon carcinoma cells. This is the first indication of an association of overexpressed PDPK FA with colon carcinoma progression. In agreement with this notion, the in vivo study also revealed that the mice injected with the antisense clone with low‐level PDPK FA only developed very small tumors (< 0.5 cm3) even after a 6‐week observation. This is in contrast to the parental or control‐transfected cells that developed large tumors (> 5 cm3) under identical conditions. Pathologic evaluation revealed invasion to the muscle layer in all tumors formed by the parental cells. In contrast, there was no sign of invasion in mice injected with the antisense clone, confirming an essential role of PDPK FA in colon carcinoma progression. Clinicopathologic study also revealed that PDPK FA is preferentially overexpressed in the invasive area of colon carcinomatous tissues and overexpression of PDPK FA is statistically and closely correlated with venous/lymphatic infiltration, lymph node metastasis, and poor prognosis of colon carcinoma patients with Dukes Stage B/C. CONCLUSIONS The results demonstrate an essential and critical role of overexpressed PDPK FA in progression and poor prognosis of colon carcinoma patients. Suppression of overexpressed PDPK FA may provide a new powerful adjuvant approach to prevent human colon carcinoma progression and poor prognosis after surgery and chemotherapy. Cancer 2002;95:1840–7. © 2002 American Cancer Society. DOI 10.1002/cncr.10904

7 August 2019 in JMIR Preprints
Verified
Preprint
Open access
IHI-Ching Hou
I-Ching Hou
MLMin-Fang Lan
Min-Fang Lan
SSShan-Hsiang Shen
Shan-Hsiang Shen
PTPei Yu Tsai
Pei Yu Tsai
KCKing Jen Chang
King Jen Chang
PDPatricia C Dykes
Patricia C Dykes
BACKGROUND Evidence has shown that breast cancer self-management support from mobile health (mHealth) apps can improve the quality of life of survivors. Although many breast cancer self-management support apps exist, few papers have documented the procedure for the development of a user-friendly app from the patient’s perspective. OBJECTIVE This study aimed to investigate the information needs of Taiwanese women with breast cancer to inform the development of a self-management support mHealth app. METHODS A 5-step design thinking approach, comprising empathy, define, ideate, prototype, and test steps, was used in the focus groups and individual interviews conducted to collect information on the requirements and expectations of Taiwanese women with breast cancer with respect to the app. A thematic analysis was used to identify information needs. RESULTS A total of 8 major themes including treatment, physical activity, diet, emotional support, health records, social resources, experience sharing, and expert consultation were identified. Minor themes included the desire to use the app under professional supervision and a trustworthy app manager to ensure the credibility of information. CONCLUSIONS The strengths of the design thinking approach were user-centered design and cultural sensitivity. The results retrieved from each step contributed to the development of the app and reduction of the gap between end users and developers. An mHealth app that addresses these 8 main themes can facilitate disease self-management for Taiwanese women with breast cancer.

1 January 2026 in Journal of Breast Cancer
Verified
Journal Article
Open access
JLJiun-I Lai
Jiun-I Lai
CHChih-Chiang Hung
Chih-Chiang Hung
CLChin-Yao Lin
Chin-Yao Lin
CLChung-Liang Li
Chung-Liang Li
WCWei-Pang Chung
Wei-Pang Chung
KRKun-Ming Rau
Kun-Ming Rau
Hormone receptor-positive metastatic breast cancer remains a major clinical burden and is characterized by sequential endocrine resistance over the disease course. In 2023, the Taiwan Breast Cancer Society (TBCS) published an expert consensus to support real-world decision-making in Taiwan. Subsequently, rapid advances in biomarker-informed strategies (e.g., estrogen receptor 1 and PI3K/AKT pathway alterations), endocrine partners, estrogen receptor (ER)-targeting agents (including oral selective ER degraders and emerging protein degraders), and the expanding role of antibody-drug conjugates based on human epidermal growth factor receptor 2 expression categories have materially increased the complexity of treatment selection and sequencing. Therefore, TBCS convened an expert panel to update the previous consensus while preserving its foundational framework and eight-chapter structure: risk evaluation and biomarker testing (I/II), first-line treatment selection (I/II), second-line treatment selection (I/II), and treatment options other than endocrine-based approaches (I/II). A multidisciplinary panel conducted a systematic literature review and iterative discussions using a modified Delphi process to identify the key clinical questions, update and refine statements where new evidence was practice-changing, and maintain continuity with the 2023 Consensus. The panel formulated updated recommendations, assigned levels of evidence and strengths of recommendations, and the key updates were integrated into practical treatment algorithms reflecting Taiwan's practice considerations. This updated consensus provides a continuity-based, yet evidence-responsive framework to facilitate the integration of emerging therapies into clinical practice in Taiwan and the Asia-Pacific region.

1 October 2025 in mHealth
Verified
Journal Article
Open access
PDF file
SCShih-Ting Chen
Shih-Ting Chen
YLYi-Ting Lu
Yi-Ting Lu
SSStoyan Stoyanov
Stoyan Stoyanov
PLPei-Ching Liu
Pei-Ching Liu
KCKing-Jen Chang
King-Jen Chang
IHI-Ching Hou
I-Ching Hou
Background: Mobile health (mHealth) applications are widely used in Taiwan, yet their quality remains unregulated. The Mobile App Rating Scale (MARS) is a validated tool for assessing mHealth app quality, but a Traditional Chinese version has not been developed and validated. This study aimed to translate and validate the traditional Chinese version of MARS (MARS-TW) and assess its reliability and validity using a cross-cultural adaptation framework. Methods: A three-phase cross-sectional study was conducted: (I) conceptual and item equivalence were evaluated by three experts; (II) semantic equivalence was assessed through forward and backward translation; (III) operational, measurement, and functional equivalence were tested on 44 mHealth apps related to cancer care (CC) and hypertension self-management (HTM), rated independently by two reviewers. Results: The expert review confirmed conceptual and item equivalence. Semantic equivalence was achieved through iterative refinements. Reliability testing demonstrated good internal consistency (Cronbach’s α ≥0.80) and inter-rater reliability [intraclass correlation coefficient (ICC) ≥0.76]. Convergent validity was supported by strong correlations within subscales [item-subscale (I-S) correlation >0.3, item-total (I-T) correlation >0.2], while divergent validity was acceptable (subscale correlations <0.70, P<0.05). Conclusions: MARS-TW is a reliable and valid tool for evaluating Traditional Chinese mHealth apps. Future research should explore its applicability across broader health-related app categories.